| Literature DB >> 33243163 |
Shaohui Ma1, Ming Zhang1, Yang Liu2,3, Dun Ding4, Peng Li1,5, Xueying Ma6, Hongjuan Liu7, Junya Mu8,9,10.
Abstract
BACKGROUND: End-stage renal disease (ESRD) patients are at a substantially higher risk for developing cognitive impairment compared with the healthy population. Dialysis is an essential way to maintain the life of ESRD patients. Based on previous research, there isn't an uncontested result whether cognition was improved or worsened during dialysis.Entities:
Keywords: Cystatin C; Dialysis initiation; End-stage renal disease; Graph analyses
Year: 2020 PMID: 33243163 PMCID: PMC7689979 DOI: 10.1186/s12882-020-02176-y
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Demographic and clinical characteristics of healthy controls and patients with end-stage renal disease
| Variable | mean ± SE | F-value | |||||
|---|---|---|---|---|---|---|---|
| HCs | predialysis group | HD group | P1 | P2 | P3 | ||
| N | 33 | 32 | 27 | – | – | – | – |
| Age (years) | 35.0 ± 1.72 | 32.7 ± 1.67 | 34.1 ± 1.66 | 0.532 | 0.715 | 0.322 | 0.512 |
| Gender (M/F) | 15/18 | 17/15 | 14/13 | – | 0.796 | 0.901 | 0.696 |
| Education (years) | 12.3 ± 0.50 | 12.0 ± 1.01 | 11.2 ± 0.55 | 0.541 | 0.15 | 0.787 | 0.523 |
| Dialysis duration | – | – | 30 ± 3.22 | – | – | – | |
| Hemoglobin(g/L) | 86.3 ± 3.51 | 103.7 ± 3.87 | – | – | |||
| Urea (μmol/L) | 31.4 ± 1.83 | 23.5 ± 1.57 | – | – | |||
| Cystatin C (mg/L) | 4.4 ± 0.616 | 4.4 ± 0.68 | – | – | – | 0.989 | |
| Na + (mmol/L) | 139.8 ± 0.57 | 144.0 ± 0.68 | – | – | |||
| K+ (mmol/L) | 4.6 ± 0.12 | 5.0 ± 0.13 | – | – | – | 0.0673 | |
| Parathyroid hormone (pg/mL) | 303.3 ± 30.37 | 731.0 ± 88.78 | |||||
P1:HCs vs. HD group; P2:HCs vs. predialysis group; P3:HD group vs. predialysis group. The two group differences in subjects’ basic information were analyzed using a two-sample t-test. The numbers of males and females were analyzed using a χ2 test. *p < 0.05
ESRD end-stage renal disease, HCs healthy controls, predialysis group predialysis ESRD patients, HD group maintenance hemodialysis ESRD patients
Neuropsychologic tests of healthy controls and patients with end-stage renal disease
| Variable | mean ± SE | F-value | |||||
|---|---|---|---|---|---|---|---|
| HCs | HD group | predialysis group | |||||
| IR-S | 26.8 ± 0.79 | 24.0 ± 0.87 | 20.0 ± 0.92 | ||||
| SR-S | 10.3 ± 0.24 | 9.2 ± 0.35 | 7.9 ± 0.45 | ||||
| LR-S | 10.3 ± 0.28 | 8.15 ± 0.34 | 7.8 ± 0.49 | 0.521 | |||
| REC-S | 11.8 ± 0.10 | 11.2 ± 0.19 | 11.1 ± 0.27 | 0.860 | |||
P1:HCs vs. HD group; P2:HCs vs. predialysis group; P3:HD group vs. predialysis group. The two group differences in subjects’ neuropsychologic tests were analyzed using a two-sample t-test. *p < 0.05
IR-S immediate recall total score, SR-S short-term delayed recall score, LR-S long-term delayed recall score, REC-S recognition score, ESRD end-stage renal disease, HCs healthy controls, predialysis group predialysis ESRD patients, HD group maintenance hemodialysis ESRD patients
Multivariable generalized linear models for prediction of neuropsychological tests
| Variable | IR-S | SR-R | LR-S | REC-S | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SE | wald | SE | wald | SE | wald | SE | wald | |||||
| Hemogloblin(g/L) | 0.043 | 0.519 | 0.471 | 0.017 | 5.127 | 0.017 | 3.770 | 0.052 | 0.009 | 0.102 | 0.750 | |
| Urea (μmol/L) | 0.107 | 2.990 | 0.084 | 0.041 | 4.598 | 0.043 | 2.128 | 0.145 | 0.022 | 3.628 | 0.057 | |
| Cystatin (mg/L) | 0.722 | 1.228 | 0.268 | 0.279 | 0.754 | 0.385 | 0.291 | 0.000 | 0.989 | 0.149 | 0.379 | 0.538 |
| Na + (mmol/L) | 0.231 | 0.325 | 0.569 | 0.089 | 0.134 | 0.715 | 0.093 | 0.561 | 0.454 | 0.048 | 0.015 | 0.902 |
| K+ (mmol/L) | 1.207 | 1.890 | 0.169 | 0.466 | 0.744 | 0.389 | 0.487 | 0.001 | 0.972 | 0.250 | 4.394 | |
| parathyroid hormone (pg/mL) | 0.002 | 0.362 | 0.547 | 0.001 | 0.530 | 0.467 | 0.001 | 0.416 | 0.519 | 0.000 | 1.046 | 0.306 |
| Hemogloblin(g/L) | 0.059 | 0.055 | 0.814 | 0.028 | 0.175 | 0.675 | 0.028 | 0.004 | 0.953 | 0.018 | 0.271 | 0.603 |
| Urea (μmol/L) | 0.102 | 1.394 | 0.238 | 0.048 | 1.379 | 0.240 | 0.049 | 3.628 | 0.057 | 0.031 | 2.207 | 0.155 |
| Cystatin C (mg/L) | 1.213 | 4.045 | 0.574 | 4.614 | 0.580 | 6.199 | 0.364 | 2.677 | 0.102 | |||
| Na + (mmol/L) | 0.355 | 0.551 | 0.458 | 0.168 | 1.317 | 0.251 | 0.170 | 2.640 | 0.104 | 0.107 | 1.070 | 0.301 |
| K+ (mmol/L) | 1.334 | 1.504 | 0.220 | 0.631 | 4.209 | 0.638 | 2.970 | 0.085 | 0.400 | 0.910 | 0.340 | |
| parathyroid hormone (pg/mL) | 0.006 | 0.114 | 0.736 | 0.003 | 0.739 | 0.390 | 0.003 | 0.996 | 0.318 | 0.002 | 2.023 | 0.155 |
IR-S immediate recall total score, SR-S short-term delayed recall score, LR-S long-term delayed recall score, REC-S recognition score, ESRD end-stage renal disease, HCs healthy controls, predialysis group predialysis ESRD patients, HD group maintenance hemodialysis ESRD patients
* uncorrected value of less than 0.05
Fig. 1The rich club phenomenon in HCs, HD group and predialysis group. a. the rich club level of HCs. b. the rich club level of the HD group. c. the rich club level of the predialysis group. d The rich club phenomenon in HCs, HD group, and predialysis group. ESRD: End-stage renal disease; predialysis group:predialysis ESRD patients; HD group: ESRD patients undergoing maintenance hemodialysis; HCs:healthy controls
Fig. 2The difference of network properties among HCs, HD group, and predialysis group. a. the E values of three groups at different k levels. b the global efficiency of the three groups at different k levels. c the normalized L of three groups at different k levels. d the normalized C of the three groups at different k levels
Fig. 3The difference of edges of the rich club among HCs, HD group, and predialysis group
Multivariable generalized linear models for prediction of average fiber length
| Variable | Rich club | Feeder | Local | ||||||
|---|---|---|---|---|---|---|---|---|---|
| SE | wald | SE | wald | SE | wald | ||||
| Hemogloblin(g/L) | 0.094 | 3.058 | 0.080 | 0.114 | 4.373 | 0.104 | 3.317 | 0.069 | |
| Urea (μmol/L) | 0.233 | 0.048 | 0.827 | 0.281 | 0.019 | 0.889 | 0.258 | 0.156 | 0.693 |
| Cystatin C (mg/L) | 1.577 | 0.479 | 0.489 | 1.898 | 0.736 | 0.391 | 1.743 | 0.999 | 0.318 |
| Na + (mmol/L) | 0.505 | 0.618 | 0.432 | 0.608 | 0.602 | 0.438 | 0.558 | 0.000 | 0.985 |
| K+ (mmol/L) | 2.638 | 0.009 | 0.925 | 3.175 | 0.000 | 1.000 | 2.914 | 0.002 | 0.961 |
| parathyroid hormone (pg/mL) | 0.004 | 0.644 | 0.422 | 0.005 | 0.760 | 0.383 | 0.004 | 0.536 | 0.464 |
| Hemogloblin(g/L) | 0.109 | 0.367 | 0.545 | 0.113 | 1.414 | 0.234 | 0.140 | 0.594 | 0.441 |
| Urea (μmol/L) | 0.190 | 2.251 | 0.134 | 0.196 | 1.038 | 0.308 | 0.244 | 0.135 | 0.713 |
| Cystatin C (mg/L) | 2.256 | 6.601 | 2.333 | 1.924 | 0.165 | 2.898 | 0.182 | 0.670 | |
| Na + (mmol/L) | 0.660 | 0.209 | 0.648 | 0.683 | 0.824 | 0.364 | 0.848 | 2.960 | 0.085 |
| K+ (mmol/L) | 2.482 | 6.313 | 2.567 | 3.457 | 0.063 | 3.188 | 0.393 | 0.531 | |
| parathyroid hormone (pg/mL) | 0.011 | 4.035 | 0.011 | 0.920 | 0.337 | 0.014 | 0.063 | 0.802 | |
predialysis group predialysis ESRD patients, HD group maintenance hemodialysis ESRD patients, ESRD end-stage renal disease
* an uncorrected p value of less than 0.05